Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 15 | 2004 | 34 | 0.580 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2003 | 5 | 0.210 |
Why?
|
| Bone Marrow | 10 | 2001 | 72 | 0.200 |
Why?
|
| Apoptosis | 8 | 1999 | 212 | 0.180 |
Why?
|
| Thrombosis | 1 | 2021 | 53 | 0.170 |
Why?
|
| Thalidomide | 3 | 2004 | 7 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 190 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2001 | 52 | 0.120 |
Why?
|
| Antineoplastic Agents | 3 | 2004 | 197 | 0.120 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1998 | 5 | 0.110 |
Why?
|
| Tretinoin | 2 | 1998 | 14 | 0.110 |
Why?
|
| Interphase | 4 | 1990 | 5 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2011 | 43 | 0.090 |
Why?
|
| Cytokines | 4 | 2001 | 237 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 46 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 62 | 0.080 |
Why?
|
| Humans | 26 | 2021 | 25950 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 4 | 1999 | 9 | 0.080 |
Why?
|
| Biomarkers | 2 | 2011 | 517 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2000 | 244 | 0.070 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 9 | 0.070 |
Why?
|
| Male | 13 | 2011 | 14087 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 170 | 0.060 |
Why?
|
| Cell Cycle | 3 | 1997 | 33 | 0.060 |
Why?
|
| Bromodeoxyuridine | 3 | 1997 | 10 | 0.060 |
Why?
|
| Female | 11 | 2011 | 14422 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 4 | 0.060 |
Why?
|
| Arsenicals | 1 | 2004 | 12 | 0.060 |
Why?
|
| Oxides | 1 | 2004 | 16 | 0.060 |
Why?
|
| Immunosuppressive Agents | 2 | 2004 | 121 | 0.060 |
Why?
|
| Aged | 11 | 2011 | 8480 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 67 | 0.050 |
Why?
|
| Pilot Projects | 4 | 2011 | 393 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 165 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2011 | 632 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 3 | 2001 | 72 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 231 | 0.050 |
Why?
|
| Aged, 80 and over | 7 | 2011 | 4409 | 0.050 |
Why?
|
| Middle Aged | 10 | 2011 | 8653 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 438 | 0.050 |
Why?
|
| Cytarabine | 3 | 2001 | 11 | 0.050 |
Why?
|
| Adult | 6 | 2021 | 7658 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2001 | 45 | 0.050 |
Why?
|
| Anemia | 1 | 2001 | 32 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 64 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 1998 | 25 | 0.040 |
Why?
|
| Connective Tissue | 2 | 1996 | 25 | 0.040 |
Why?
|
| Palliative Care | 1 | 2000 | 108 | 0.040 |
Why?
|
| Cytogenetic Analysis | 3 | 2004 | 6 | 0.040 |
Why?
|
| Remission Induction | 3 | 2004 | 88 | 0.040 |
Why?
|
| Hematopoiesis | 4 | 2001 | 10 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 847 | 0.040 |
Why?
|
| Ecchymosis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Cell Division | 4 | 2001 | 79 | 0.040 |
Why?
|
| Idoxuridine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cell Lineage | 3 | 2004 | 24 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 11 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 19 | 0.030 |
Why?
|
| Leukemia, Myeloid | 2 | 1995 | 3 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1996 | 21 | 0.030 |
Why?
|
| DNA | 3 | 1997 | 100 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2004 | 3422 | 0.030 |
Why?
|
| Macrophages | 3 | 2001 | 115 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 126 | 0.020 |
Why?
|
| Phenotype | 2 | 2011 | 289 | 0.020 |
Why?
|
| Risk Factors | 2 | 2011 | 2183 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2001 | 27 | 0.020 |
Why?
|
| Time Factors | 2 | 2001 | 1387 | 0.020 |
Why?
|
| Mitoxantrone | 2 | 2001 | 4 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 49 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 12 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 130 | 0.020 |
Why?
|
| Amifostine | 2 | 2000 | 3 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 117 | 0.020 |
Why?
|
| Monosomy | 1 | 1990 | 1 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 3 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 81 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 16 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2001 | 550 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 182 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 2001 | 12 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 325 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 8 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 41 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1988 | 2 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 24 | 0.020 |
Why?
|
| Disease Progression | 2 | 2004 | 636 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 54 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 596 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1988 | 133 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 909 | 0.020 |
Why?
|
| DNA Fragmentation | 2 | 1996 | 4 | 0.020 |
Why?
|
| DNA Replication | 2 | 1996 | 10 | 0.020 |
Why?
|
| S Phase | 2 | 1999 | 11 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1996 | 48 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1093 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 1 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2004 | 3 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 17 | 0.010 |
Why?
|
| Infliximab | 1 | 2004 | 17 | 0.010 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 3 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 11 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 33 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 142 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 164 | 0.010 |
Why?
|
| Acute Disease | 2 | 1995 | 175 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 132 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2001 | 7 | 0.010 |
Why?
|
| Lymphokines | 1 | 2001 | 10 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 14 | 0.010 |
Why?
|
| Platelet Count | 1 | 2001 | 14 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 11 | 0.010 |
Why?
|
| Endothelium | 1 | 2001 | 13 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2001 | 12 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2001 | 32 | 0.010 |
Why?
|
| Adipocytes | 1 | 2001 | 19 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 63 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2001 | 31 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 14 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 53 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2001 | 31 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 69 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 159 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 360 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 3 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2000 | 6 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 11 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 10 | 0.010 |
Why?
|
| Hypotension | 1 | 2000 | 25 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 33 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 29 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 11 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 15 | 0.010 |
Why?
|
| Age Factors | 1 | 2001 | 727 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 785 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1996 | 7 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 6 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 19 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 14 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1996 | 16 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 340 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 4 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 36 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2001 | 1745 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 193 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 312 | 0.010 |
Why?
|
| Adolescent | 1 | 1999 | 2123 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 8 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1992 | 319 | 0.010 |
Why?
|
| Metaphase | 1 | 1990 | 2 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 9 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 26 | 0.010 |
Why?
|
| Regeneration | 1 | 1989 | 16 | 0.000 |
Why?
|